Closing the gap: do we need a framework for embedding equity in health technology assessment?
International Journal of Technology Assessment in Health Care · 2026
DOI: 10.1017/s0266462325103322 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Technology Assessment in Health Care, 2026. Verfasst von Jonathan Pearson-Stuttard und 4 weiteren Autor:innen. Beteiligte Einrichtung: Health Analytics, Lane Clark & Peacock LLP, London, UK. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Health Equity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objectives
Reducing health inequalities and improving health equity have become pressing priorities for health technology assessment (HTA) bodies and healthcare payers globally, particularly in light of the COVID-19 pandemic and its disproportionate impact on disadvantaged groups. Equity considerations are now being embedded across strategic frameworks and HTA processes in countries such as the UK, Canada, and Australia. Examples include NICE’s Core20PLUS5 initiative and PBAC’s policy shift allowing broader prescribing access to address care disparities. However, systematically incorporating quantitative equity measures into HTA presents significant challenges, given the diversity of equity subgroups and varying national contexts.
Methods
At the 2024 CDA-AMC Symposium, we convened stakeholders to discuss the challenges and opportunities for integrating equity into HTA.
Results
Key insights included ICER’s framework for embedding equity across the HTA lifecycle and NICE’s evolving application of Distributional Cost-Effectiveness Analysis (DCEA), as demonstrated in the appraisal of exagamglogene autotemcel for beta-thalassemia. DCEA, while increasingly recognized, requires robust real-world data and clearer guidance on trade-offs between equity and efficiency. Manufacturers are aligning equity goals with ESG priorities but seek greater clarity from HTA bodies on how equity evidence influences decision-making. NICE and ICER emphasize the need for deliberative processes to capture equity dimensions not reflected in traditional cost-effectiveness analysis.
Conclusion
Advancing health equity in HTA will require cross-sector collaboration to develop guidance, improve data infrastructure, and standardize methodologies. Equity-focused evidence generation across the “staircase of inequality” – from need to access and outcomes – can support more inclusive HTA and reimbursement decisions, ultimately fostering a fairer and more effective healthcare system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Health Analytics, Lane Clark & Peacock LLP, London, UK.
- Institute for Clinical and Economic Review, Boston, MA, USA.
- Centre for Health Economics, University of York, York, UK.
- Novo Nordisk, Bagsværd, Denmark.
- National Institute for Health and Care Excellence, Manchester, UK.
ORCID-Profile: Jonathan Pearson-Stuttard
Zitieren
APA
Pearson-Stuttard, J., Richardson, M., Griffin, S., Lübker, C., & Duffield, S. (2026). Closing the gap: do we need a framework for embedding equity in health technology assessment?. International Journal of Technology Assessment in Health Care. https://doi.org/10.1017/s0266462325103322
Vancouver
Pearson-Stuttard J, Richardson M, Griffin S, Lübker C, Duffield S. Closing the gap: do we need a framework for embedding equity in health technology assessment?. International Journal of Technology Assessment in Health Care. 2026. doi:10.1017/s0266462325103322
BibTeX
@article{PearsonStuttard2026,
author = {Pearson-Stuttard, Jonathan and Richardson, Marina and Griffin, Susan and Lübker, Chris and Duffield, Stephen},
title = {Closing the gap: do we need a framework for embedding equity in health technology assessment?},
journal = {International Journal of Technology Assessment in Health Care},
year = {2026},
doi = {10.1017/s0266462325103322}
}
EUVIMED